

## Special Issue

# Predictive and Prognostic Biomarkers for Response to Neoadjuvant Chemotherapy-with and without HER2-Targeting Therapy

### Message from the Guest Editor

Breast cancer (BC) is the most commonly occurring cancer in women, with nearly 2.26 million cases diagnosed each year. BC management remains a significant clinical challenge, hindered by the inability of these tumours to respond to targeted therapeutic agents, and the fact that the population of women with BC is more diverse than expected. Preoperative neoadjuvant cytotoxic chemotherapy (NACT) is a standard treatment option for the triple negative and HER2+ BC subtypes, in addition to HER2-targeting agents, as it reduces the tumour size prior to loco-regional treatment with surgery and radiotherapy, enables the patient to undergo an in vivo chemosensitivity test, and enables the deployment of more intensive adjuvant chemotherapy and the consideration of novel adjuvant treatment for chemo-resistant tumours. Therefore, there is an urgent need to identify new prognostic and predictive features that could accurately sub-stratify BC patients, monitor and grade their responses to chemotherapy, and provide tailored and guided treatment to individual patients to avoid serious toxicities and economic burden resulting from unnecessary and ineffective therapies.

### Guest Editor

Dr. Tarek M. A. Abdel-Fatah

Clinical Oncology, Nottingham University Hospitals NHS Trust,  
Nottingham, UK

### Deadline for manuscript submissions

closed (29 February 2024)



## Biomedicines

an Open Access Journal  
by MDPI

Impact Factor 3.9  
CiteScore 6.8  
Indexed in PubMed



[mdpi.com/si/171324](https://mdpi.com/si/171324)

*Biomedicines*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[biomedicines@mdpi.com](mailto:biomedicines@mdpi.com)

[mdpi.com/journal/  
biomedicines](https://mdpi.com/journal/biomedicines)





# Biomedicines

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.9  
CiteScore 6.8  
Indexed in PubMed



[mdpi.com/journal/  
biomedicines](https://mdpi.com/journal/biomedicines)



## About the Journal

### Message from the Editor-in-Chief

*Biomedicines* (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

---

### Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

---

### Author Benefits

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

#### Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).